Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.84 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.77 |
| ▸ | CNR2 | P34972 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.72 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | PTGES | O14684 | 1/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ALB | P02768 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2739299 | 0.91 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL29373123 | 0.88 | PTGS2 (0.80) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL14086813 | 0.87 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL30426824 | 0.87 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL11092811 | 0.87 | PTGS2 (0.88) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL3344313 | 0.87 | PTGS2 (0.81) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL11159263 | 0.87 | PTGS2 (0.80) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL14394799 | 0.86 | PTGS2 (0.84) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL10592773 | 0.85 | PTGS2 (0.78) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL14031839 | 0.85 | PTGS2 (0.84) | PTGS2AKR1C3CNR2PTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3693381-B1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2025-09-03 | — | — | EP | disclosed |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RES INST (US) | 2025-05-22 | — | — | US | disclosed |
| CN-114716544-B | Complement component C5 antibodies | 阿勒根公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240301370-A1 | Ligand Binding Molecules and Uses Thereof | VEGENICS PTY LIMITED (AU) | 2024-09-12 | — | — | US | disclosed |
| US-20240294652-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K-A, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240279317-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2024-08-22 | — | — | US | disclosed |
| US-11866739-B2 | Ligand binding molecules and uses thereof | VEGENICS PTY LIMITED (AU) | 2024-01-09 | — | — | US | disclosed |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230124150-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2023-04-20 | — | — | US | disclosed |
| CN-115568625-A | Blasting bead for cigarette and application thereof | 江苏浩丰生物科技有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-114716544-A | Complement component C5 antibody | 阿勒根公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4008726-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220088119-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | SCHEPENS EYE RESEARCH INSTITUTE | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088119-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | PTGS2 313/4885AKR1C3 2038/4885CNR2 2580/4885 |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | IL17A, IL23R, IL15RA | PTGS2 3854/4885AKR1C3 1324/4885CNR2 3310/4885 |
| US-20250161402-A1 | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE | CRYAB, CRYAA, FUCA2 | PTGS2 313/4885AKR1C3 2038/4885CNR2 2580/4885 |
| US-20240294652-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | PTGS2 3854/4885AKR1C3 1324/4885CNR2 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.